Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Telaprevir twice daily is noninferior to telaprevir every 8 hours for patients with chronic hepatitis C.

Gastroenterology - 1 Mar 2014

Buti Maria, Agarwal Kosh, Horsmans Yves, Sievert William, Janczewska Ewa, Zeuzem Stefan, Nyberg Lisa, Brown Robert S, Hézode Christophe, Rizzetto Mario, Paraná Raymundo, De Meyer Sandra, De Masi Ralph, Luo Donghan, Bertelsen Kirk, Witek James

Abstract excerpt

BACKGROUND & AIMS: We performed an open-label, multicenter, phase 3 study of the safety and efficacy of twice-daily telaprevir in treatment-naive patients with chronic hepatitis C virus (HCV) genotype 1 infection, including those with cirrhosis. METHODS: Patients were randomly assigned to groups treated with telaprevir 1125 mg twice daily or 750 mg every 8 hours plus peginterferon alfa-2a and ribavirin for 12...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Administration Schedule
Share to Fatigue

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Headache

Share to Interferon-alpha

Share to Nausea

Share to Oligopeptides

Share to Polyethylene Glycols

Share to Ribavirin

Source

Identifiers

PMID: 24316262
DOI: 10.1053/j.gastro.2013.11.047

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Telaprevir twice daily is noninferior to telaprevir every 8 hours for patients with chronic hepatitis C.PMID 24316262Read ↗

Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection.Semantic proximity Read ↗

Efficacy and tolerability of telaprevir for chronic hepatitis virus C genotype 1 infection: a meta-analysis.Semantic proximity Read ↗

Telaprevir for the treatment of chronic hepatitis C infection.Semantic proximity Read ↗

Telaprevir for retreatment of HCV infection.Semantic proximity Read ↗

Telaprevir: a hepatitis C NS3/4A protease inhibitor.Semantic proximity Read ↗

Telaprevir: a new hope in the treatment of chronic hepatitis C?Semantic proximity Read ↗

Efficacy and safety of telaprevir (TVR) triple therapy in a 'real-life' cohort of 102 patients with HCV genotype 1: interim analysis after 24 weeks of treatment.Semantic proximity Read ↗

Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis.Semantic proximity Read ↗

Telaprevir: a review of its use in the management of genotype 1 chronic hepatitis C.Semantic proximity Read ↗

Telaprevir for previously treated chronic HCV infection.Semantic proximity Read ↗

Safety and on-treatment efficacy of telaprevir: the early access programme for patients with advanced hepatitis C.Semantic proximity Read ↗

Twice-Daily Telaprevir for Posttransplant Genotype 1 Hepatitis C Virus: A Prospective Safety, Efficacy, and Pharmacokinetics Study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.